Cumulative results of Xen gel stent implantation in Europe promising for US

FORT LAUDERDALE, Fla. — If approved by the FDA, Allergan’s Xen45 implant will be an additional tool to surgically manage glaucoma in the U.S., Davinder S. Grover, MD, MPH, said at the American Glaucoma Society meeting, where he reported on the international experience of the first 975 glaucomatous eyes treated with any one of three iterations of the gel stent. At 12 months, “for all comers,” there is nearly a 33% reduction in IOP and a reduction of 1.7 glaucoma medications, Grover said. Efficacy was similar to that of traditional glaucoma surgery with fewer complications.